Preview Newsletter

XARELTO Media Monitoring – Week of 02-19-16

Client Attorney Privileged/Attorney Work Product/At Request of Counsel

Plaintiff Attorney Press Releases

Xarelto Lawsuit Plaintiffs Find Support Through Results Of JAMA Ophthalmology Study
Feb 15, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerhelp.com reports on support being given to plaintiffs who have currently filed lawsuits against the manufacturers of blood thinner Xarelto through the results from multiple studies which raise concern over the safety of the drug, and its dangerous side effects. The anticoagulant is manufactured by Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer Healthcare.
Xarelto Lawsuit Plaintiffs Watch As Case Numbers Surpass 3,000 Across The Nation
Feb 16, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on the latest numbers in Xarelto lawsuits, which show that complaints filed against manufacturers Janssen Pharmaceuticals and Bayer AG regarding anticoagulant Xarelto have surpassed 3,000 in total. This number includes a grouping of more than 2,800 Xarelto lawsuits which was consolidated by the U.S. Judicial Panel on Multidistrict Litigation to create MDL No. 2592 in Louisiana and an additional consolidation of more than 550 cases which were consolidated to form a mass tort group by the Court of Common Pleas in Philadelphia, Pennsylvania.
Plaintiff Files Xarelto Lawsuit Alleging Anticoagulant Caused Husband's Fatal Internal Bleed
Feb 16, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on a lawsuit which has been filed against Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer Healthcare. The plaintiff, a south Florida resident, filed the complaint on behalf of her deceased husband. She alleges that blood-thinning drug Xarelto, produced by Bayer and Janssen, caused his death. She states that these manufacturers failed to properly warn consumers about the significant bleeding risks she now says are connected to their anticoagulant. The lawsuit was filed under case number 9:14-cv-80831 in Florida before being transferred to the Eastern District of Louisiana during the JPML’s consolidation. Today, it has joined MDL No. 2592 and is being overseen by the Honorable Judge Eldon Fallon.
Louisiana Xarelto Lawsuit Plaintiff Alleges Drug Caused Fatal Bleeding of Grandmother
Feb 17, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on another lawsuit which has been filed against pharmaceutical manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) in relation to their anticoagulant drug, Xarelto. The lawsuit was filed by a granddaughter on behalf of her deceased grandmother. The plaintiff alleges that her grandmother passed away after suffering from bleeding complications while using Xarelto. In September of 2014, the grandmother was prescribed the blood thinner by her doctor for the treatment of deep vein thrombosis (DVT). Just two short months later, however, the woman unexpectedly suffered from an intracranial bleed (brain bleed). Doctors deemed the bleed as “irreversible and fatal,” and the woman passed away shortly afterward.
Nebraska Xarelto Lawsuit Plaintiffs Claim Blood Thinner Caused Severe And Permanent Side Effects
Feb 17, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on a lawsuit which has been filed against Janssen Pharmaceuticals and Bayer AG in reference to the blood thinning drug they manufacture, Xarelto. Janssen is a subdivision of the Johnson & Johnson corporation. The plaintiffs who have filed this lawsuit are a married couple from Nebraska who together allege that the defendants manufactured an unsafe anticoagulant. They claim that due to his Xarelto use, the husband suffered serious and lasting side effects, including sudden uncontrollable bleeding and shortened life expectancy.
Xarelto Lawsuit Plaintiff Seeking $4.35 Million For Alleged Uncontrollable Bleeding Episode
Feb 17, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on a lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson), as well as several other defendants, regarding the blood thinning drug they manufacture, Xarelto. Allegations within the suit state that the anticoagulant caused the plaintiff to suddenly suffer from an uncontrollable bleeding episode. The complaint was transferred with all Xarelto lawsuits during the U.S. Judicial Panel on Multidistrict Litigation’s consolidation, and filed with MDL No. 2592 in New Orleans, Louisiana. The Honorable Judge Eldon E. Fallon is presiding over the MDL, and will host another monthly status conference on the cases involved near the end of February, 2016.
Bellwether Case Selection Completed For Xarelto Lawsuit MDL 2592 In Louisiana
Feb 17, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on the completed process of case selection for lawsuits consolidated in Xarelto multidistrict litigation number 2592, which are set to be heard in 2017. The MDL is being overseen by the Honorable Judge Eldon Fallon in the Eastern District of Louisiana. Today, the involved lawsuits number over 2,800 and all share common allegations against manufacturers Bayer AG and Janssen Pharmaceuticals’ (a division of Johnson & Johnson corporation) regarding their blood-thinning drug, Xarelto.
Xarelto Litigation – February Updates
Feb 17, 2016 | JD Supra Business Advisor
By Searcy Denney Scarola Barnhart & Shipley

There have been a number of recent noteworthy developments in the national litigation involving Xarelto. Currently, there are approximately 5,000 individual lawsuits pending in state and federal courts against the manufacturers of Xarelto. The largest concentration of state court cases is in Philadelphia, where nearly 600 individual lawsuits are pending. The state court litigation involves primarily those plaintiffs who are unable to participate in the MDL proceedings due to a lack of diversity jurisdiction, as the plaintiff resides in the same state where the drug manufacturer has a legal presence. The lawsuits that have been filed include a number of US and foreign drug companies, including Janssen Research & Development, LLC; Johnson & Johnson Pharmaceutical Research and Development, LLC; Johnson & Johnson Company; Janssen Ortho, LLC; Janssen Pharmaceuticals, Inc.; Janssen Pharmaceutica, Inc.; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Bayer Corporation; Bayer Healthcare AG; Bayer Pharma AG; Bayer Healthcare LLC: and Bayer Healthcare Pharmaceuticals Inc.
Xarelto Lawsuit Cases Alleging Dangerous Bleeding Risks Consolidated By JPML Under Honorable Judge Eldon Fallon
Feb 17, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on the consolidation of all federally-filed Xarelto bleeding lawsuits by the U.S. Judicial Panel on Multidistrict Litigation. The 2,800 cases are being overseen by the Honorable Judge Eldon E. Fallon in the Eastern District of Louisiana, who will hold another monthly status meeting regarding their progress toward the end of February of 2016. This consolidation initially took place on December 12, 2015, initiating a transfer of cases filed in federal courtrooms across the nation. Since the consolidation, lawsuit numbers in the MDL have continued to experience a significant growth in number.
Xarelto Lawsuit Plaintiffs Look For Results Of Investigation Of European Regulators Into Drug’s Clinical Trials
Feb 17, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on an investigation by European regulators regarding the results of Xarelto clinical trials. This investigation closely follows an ongoing increase in lawsuits filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation) which commonly allege that use of their blood thinner Xarelto can put patients at an increased risk of spontaneous and dangerous uncontrollable bleeding events.
Xarelto Lawsuit Alleges Manufacturers Bayer And Janssen Are Responsible For Patient’s Life-Threatening Injuries
Feb 18, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports details from a lawsuit filed against Xarelto manufacturers Bayer Healthcare and Janssen Pharmaceuticals (a subsidiary of corporate giant Johnson & Johnson). The complaint was filed by a married couple from Ohio who allege that their blood thinner caused the wife to suffer from a sudden, life-threatening internal bleeding episode. Together, the pair are requesting compensation of over $150,000 to help manage current and future medical bills, as the bleed has allegedly left her with long-term damage and a need for continued medical care.
Xarelto Lawsuit Plaintiff Claims Anticoagulant Drug Caused Life-Threatening Internal Bleed
Feb 18, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on a lawsuit which has been filed against Xarelto manufacturers Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer Healthcare initially filed in the Eastern District of New York. The suit was filed by a woman from Texas who claims that the manufacturers failed to warn patients (including herself) about the potential risks associated with their blood-thinning drug. The lawsuit was filed under case number 1:14-cv-04524.

Plaintiff Attorney Blog Posts

Xarelto
Feb 13, 2016 | Injury Lawsuit Help

If you take the prescription medication XARELTO which is used to reduce the risk of stroke and blood clots in people with atrial fibrillation, not caused by a heart valve problem. This prescription medicine used to treat deep vein thrombosis and pulmonary embolism, and to help reduce the risk of these conditions occurring again. If you experience any type of severe issues, call your doctor immediately. Then call us.
Drug Injury Lawsuits
Feb 15, 2016 | Drug Justice

Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are being sued in the lawsuit primarily due to their neglect to warn consumers of all Xarelto side effects and not properly informing doctors of a solution to reverse uncontrolled and internal bleeding. The lawyers on the case are currently looking for patients that have experienced internal bleeding and blood clots and the families of victims who have died after taking this drug. The Xarelto lawsuit has most recently been consolidated into a multi-district litigation in order to better streamline the process.
Judge Outlines Categories for Xarelto Bellwether Trials
Feb 16, 2016 | Top Class Actions
By Ashley Vanover

A case management order has been issued in the Xarelto multi district litigation (MDL) that outlines the injury categories into which Xarelto lawsuits must be classified to be considered for potential bellwether trials.
Parties Select Xarelto Bellwether Cases, Litigation Moves Forward
Feb 17, 2016 | The Legal Examiner
By Andy Childers

The U.S. District Court in the Eastern District of Louisiana has started the process of selecting 40 cases for the bellwether trial pool. As required by an order dated December 17, 2015, the parties in the Xarelto multidistrict litigation (MDL) have selected 10 cases for the pool by the January 11, 2016 deadline
Xarelto- Blood Thinner Lawyer News
Feb 17, 2016 | Jewish Lawyers USA

Xarelto is a blood thinner with no antidote. Xarelto has been shown to cause extensive bleeding resulting in severe injury and deaths. The Xarelto lawyers are moving ahead with the Xarelto bleeding lawsuits in a multi district litigation. This MDL consolidates the Xarelto lawsuits in one location under one judge.
Xarelto Lawsuit Alleges Drug Caused Woman Two Gastrointestinal Bleeds
Feb 17, 2016 | Top Class Actions
By Joanna Szabo

A New Jersey resident recently filed a Xarelto blood thinner lawsuit against Janssen Pharmaceuticals, alleging that use of the anticoagulant drug led to serious gastrointestinal bleeding. Plaintiff Sharon M. first began taking Xarelto in November 2013 and stopped taking the drug in April 2014 after experiencing two serious gastrointestinal bleeding events in less than two months.
Xarelto Lawsuit: Blood Thinner Caused Intracranial Hemorrhage
Feb 19, 2016 | Top Class Actions
By Tamara Burns

A new Xarelto lawsuit was filed as part of the multidistrict litigation underway in a Louisiana federal court alleging that the blood thinner caused one man to suffer a life-threatening intracranial hemorrhage.

Full Text of Stories Below

Client Attorney Privileged/Attorney Work Product/At Request of Counsel

Plaintiff Attorney Press Releases

Xarelto Lawsuit Plaintiffs Find Support Through Results Of JAMA Ophthalmology Study

Feb 15, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerhelp.com reports on support being given to plaintiffs who have currently filed lawsuits against the manufacturers of blood thinner Xarelto through the results from multiple studies which raise concern over the safety of the drug, and its dangerous side effects. The anticoagulant is manufactured by Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer Healthcare.
The first study was conducted by physicians John C. Hwang and Judy Hun, and results highlight a possible link to sudden and serious eye hemorrhages. To properly investigate these occurrences, the doctor duo observed patients from their practice ages 70-89 who had taken blood thinners for some time, and who began by using traditional blood thinners before later switching to Xarelto. They realized that a study of this sort was likely necessary when their patients began to increasingly suffer from eye bleeds, or vitreous hemorrhages. Their results confirmed that, especially patients switching from traditional blood thinners to Xarelto, were at an increased risk for this occurrence.
According to documentation from the doctors, patients who were weaning off of traditional blood thinners (warfarin), and beginning to take Xarelto most commonly suffered these eye bleeds. Complete reports on these outcomes were published in JAMA Ophthalmology’s June 2015 issue. The doctors noted, “In all cases, an acute vitreous hemorrhage occurred shortly after rivaroxaban (Xarelto) treatment was initiated.”
In an April 2015 issue of BMJ, (previously the British Medical Journal), another notable Xarelto study was discussed. This one concluded that researchers of several different types of anticoagulants were unable to rule out as high as a twofold increased risk for stomach bleeds in patients taking Xarelto when compared to those taking warfarin. The study evaluated the medical history of nearly 46,000 patients to find these results.
These studies lend significant support to the arguments of nearly 2,800 plaintiffs who have filed Xarelto-related complaints, commonly alleging that the drug caused dangerous and uncontrollable bleeding events, which, in some cases, proved fatal. Xarelto lawsuits from federal courts across the nation have been consolidated to form multidistrict litigation No. 2592. They are being overseen in New Orleans, Louisiana by the Honorable Judge Eldon Fallon.
Attorney Joseph Osborne is now working to ensure that anyone who has taken Xarelto and who has also suffered from serious side effects that they link to the blood thinner will be given the opportunity to evaluate their legal rights fully. He is currently offering complimentary consultations to affected individuals, who may be entitled to legal action and significant compensation.
To request additional information on Xarelto lawsuits, or to ask questions, contact Attorney Osborne by calling (866) 425-8902.
http://www.klkntv.com/story/31210775/xarelto-lawsuit-plaintiffs-find-support-through-results-of-jama-ophthalmology-study

Return to headline | Return to top
Xarelto Lawsuit Plaintiffs Watch As Case Numbers Surpass 3,000 Across The Nation

Feb 16, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on the latest numbers in Xarelto lawsuits, which show that complaints filed against manufacturers Janssen Pharmaceuticals and Bayer AG regarding anticoagulant Xarelto have surpassed 3,000 in total. This number includes a grouping of more than 2,800 Xarelto lawsuits which was consolidated by the U.S. Judicial Panel on Multidistrict Litigation to create MDL No. 2592 in Louisiana and an additional consolidation of more than 550 cases which were consolidated to form a mass tort group by the Court of Common Pleas in Philadelphia, Pennsylvania.
The lawsuits continue to grow in number and share common allegations from plaintiffs indicating that Janssen and Bayer have failed to adequately warn consumers about a potentially escalated risk for the occurrence of sudden uncontrollable bleeding episodes in patients using the blood thinner.
Plaintiffs involved find comfort in the fact that their Xarelto complaints closely mirror previously settled Pradaxa lawsuits which also grew to number in the thousands. Pradaxa cases were able to be settled outside of court, and many plaintiffs who have filed Xarelto lawsuits are hoping for a similar outcome.
The United States Food and Drug Administration gave Xarelto approval to treat patients healing after knee and hip replacement surgeries who could be at increased risk of blood clots or stroke, as well as patients with deep vein thrombosis. This approval was later expanded to include treatment of patients with atrial fibrillation, a heart condition which can cause an increased risk of stroke.
Recent studies by physicians have highlighted a potential link between the use of Xarelto and sudden stomach and eye hemorrhages. Additionally, thousands of plaintiffs have noted uncontrollable bleeding episodes, some of which were fatal.
Many believe that as these plaintiffs await trial, lawsuit numbers will continue to increase. Attorney Joseph Osborne is currently helping ensure that anyone who believes they have been negatively affected by the drug can have the opportunity to investigate their legal options fully. These patients could be entitled to significant compensation through legal action. To help them pursue justice, Attorney Osborne is offering free legal consultations for those involved at this time.
To request additional information or ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2838291#ixzz40RDzR0lT

Return to headline | Return to top
Plaintiff Files Xarelto Lawsuit Alleging Anticoagulant Caused Husband's Fatal Internal Bleed

Feb 16, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on a lawsuit which has been filed against Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer Healthcare. The plaintiff, a south Florida resident, filed the complaint on behalf of her deceased husband. She alleges that blood-thinning drug Xarelto, produced by Bayer and Janssen, caused his death. She states that these manufacturers failed to properly warn consumers about the significant bleeding risks she now says are connected to their anticoagulant. The lawsuit was filed under case number 9:14-cv-80831 in Florida before being transferred to the Eastern District of Louisiana during the JPML’s consolidation. Today, it has joined MDL No. 2592 and is being overseen by the Honorable Judge Eldon Fallon.
The plaintiff alleges that the drug manufacturers are to blame for her husband's death. Court documents state that this death occurred after the man suffered from a fatal episode of uncontrollable internal bleeding that doctors were unable to stop. He passed away from a subdural hemorrhage. His widow states that he was prescribed Xarelto to help prevent the risk of stroke due to his atrial fibrillation heart condition.
In 2011, the U.S. Food and Drug Administration approved Xarelto, and it launched onto the market as a successful new-generation blood thinner. Traditional blood thinners require consumers to be consistently monitored and also require special diets, Xarelto did not. The benefits may have helped consumers to ignore many of the drug’s risks, however, which according to plaintiffs today, make Xarelto the most dangerous blood thinner available on the market. Even the FDA has issued two black box warnings for the drug, which are the most strict warnings possible before fully removing the drug from the market.
Today, Xarelto is the subject of more than 2,800 federally-filed lawsuits from across the nation, as well as an additional 550 or more cases which have formed a mass tort group by the Court of Common Pleas in Philadelphia, Pennsylvania.
As the many plaintiffs involved await justice, Attorney Joseph Osborne is working to help ensure that everyone who believes they have been negatively affected by Xarelto will be given the opportunity to investigate their legal rights fully. These patients may be entitled to substantial compensation. To help simplify this process for those deserving, Attorney Osborne is offering free legal Xarelto consultations at this time.
To request more information, or to ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2838317#ixzz40REVn0LH

Return to headline | Return to top
Louisiana Xarelto Lawsuit Plaintiff Alleges Drug Caused Fatal Bleeding of Grandmother

Feb 17, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on another lawsuit which has been filed against pharmaceutical manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) in relation to their anticoagulant drug, Xarelto. The lawsuit was filed by a granddaughter on behalf of her deceased grandmother. The plaintiff alleges that her grandmother passed away after suffering from bleeding complications while using Xarelto. In September of 2014, the grandmother was prescribed the blood thinner by her doctor for the treatment of deep vein thrombosis (DVT). Just two short months later, however, the woman unexpectedly suffered from an intracranial bleed (brain bleed). Doctors deemed the bleed as “irreversible and fatal,” and the woman passed away shortly afterward.
Court document details regarding this lawsuit note that the granddaughter now alleges that Xarelto caused her grandmother’s fatal bleed. She details that doctors could not clot the woman’s blood to stop her bleed, as it had been thinned by the drug. The granddaughter indicates that when initially considering blood thinners, she and her grandmother observed multiple advertisements which heavily promoted the positive aspects of Xarelto without adequately addressing the drug’s potential risks. She stated that the manufacturers’ marketing tactics “overstated the efficacy of Xarelto with respect to preventing stroke and systemic embolism.”
Her case was filed in the United States District Court for the Eastern District of Louisiana under case number 2:15-cv-05874. At this point, it has been consolidated with over 2,800 Xarelto lawsuits to form multidistrict litigation No. 2592. All federally-filed Xarelto lawsuits from across the nation have been consolidated to form this MDL by the U.S. Judicial Panel for Multidistrict Litigation due to the fact that they contain strikingly similar allegations. In addition to these cases, another 550 lawsuits regarding Xarelto have been formed into a mass tort group in Philadelphia, Pennsylvania by the Court of Common Pleas. The Louisiana MDL cases are being overseen by the Honorable Judge Eldon Fallon, and are currently awaiting another status conference update near the end of February, 2016.
At this time, Attorney Joseph Osborne is working to help ensure that everyone who may have suffered adverse health events after using Xarelto will have the opportunity to completely evaluate their legal rights. These patients may be entitled to legal action and substantial compensation. For those affected, Attorney Osborne is offering free legal consultations at this time.
To request additional information or ask questions, please contact Joseph Osborne, Esq. by calling(866) 425-8902.
http://www.12newsnow.com/story/31238597/louisiana-xarelto-lawsuit-plaintiff-alleges-drug-caused-fatal-bleeding-of-grandmother

Return to headline | Return to top
Nebraska Xarelto Lawsuit Plaintiffs Claim Blood Thinner Caused Severe And Permanent Side Effects

Feb 17, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on a lawsuit which has been filed against Janssen Pharmaceuticals and Bayer AG in reference to the blood thinning drug they manufacture, Xarelto. Janssen is a subdivision of the Johnson & Johnson corporation. The plaintiffs who have filed this lawsuit are a married couple from Nebraska who together allege that the defendants manufactured an unsafe anticoagulant. They claim that due to his Xarelto use, the husband suffered serious and lasting side effects, including sudden uncontrollable bleeding and shortened life expectancy.
Details from the couple’s complaint, which was filed in the U.S. District Court for the Eastern District of Louisiana under number 2:15-cv-06514, indicates that the husband used Xarelto for 7 months, from May of 2013 through December of 2013, when he unexpectedly suffered from a gastrointestinal bleed which the couple alleges was caused by the blood thinner. Due to the fact that the man had Xarelto in his system at the time of the bleed, physicians had tremendous difficulty clotting the blood.
This husband and wife are not alone in their complaint. Xarelto has recently been the topic of continually increasing lawsuits from across the U.S., all which similarly allege that the drug puts users at increased risk for uncontrollable bleeding episodes. These federally-filed lawsuits have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592, which includes over 2,800 cases today. Many believe that these numbers will only continue to increase as the plaintiffs involved await trials. The MDL is being overseen in the Eastern District of Louisiana by the Honorable Judge Eldon Fallon.
The plaintiffs who have filed this lawsuit are seeking compensatory and punitive damages and also compensation to cover the costs of litigation. As they await justice, Attorney Joseph Osborne is working to ensure that everyone negatively affected by Xarelto will have the same opportunity to pursue justice. Those affected may be entitled to legal action and significant compensation. To help facilitate this process, Attorney Osborne is currently providing complimentary legal consultations for affected individuals.
To request more information or ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.cbs19.tv/story/31238559/nebraska-xarelto-lawsuit-plaintiffs-claim-blood-thinner-caused-severe-and-permanent-side-effects

Return to headline | Return to top
Xarelto Lawsuit Plaintiff Seeking $4.35 Million For Alleged Uncontrollable Bleeding Episode

Feb 17, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on a lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson), as well as several other defendants, regarding the blood thinning drug they manufacture, Xarelto. Allegations within the suit state that the anticoagulant caused the plaintiff to suddenly suffer from an uncontrollable bleeding episode. The complaint was transferred with all Xarelto lawsuits during the U.S. Judicial Panel on Multidistrict Litigation’s consolidation, and filed with MDL No. 2592 in New Orleans, Louisiana. The Honorable Judge Eldon E. Fallon is presiding over the MDL, and will host another monthly status conference on the cases involved near the end of February, 2016.
This particular lawsuit, though it has now joined with over 2,800 others, is especially notable due to the fact that it involves 90-counts and the plaintiff who filed it has requested $4.35 million in compensation. According to details in the complaint, this plaintiff claims that Bayer AG and Janssen misleadingly marketed Xarelto as a safe and effective treatment for those who wish to reduce their risk of suffering from a stroke, and neglected to properly express dangerous side effects linked to the drug to the public. Xarelto was approved by the U.S. Food and Drug Administration in 2011, and was then launched onto the market as a revolutionary, new-generation blood thinner.
The plaintiff indicates that manufacturers were likely aware that the blood thinner could cause increased risk of bleeding for those taking it. Results from clinical studies on the drug, as well as medical studies done more recently appear to support this argument. If the manufacturers were aware of these potentially linked dangers, however, the plaintiff states, they did nothing with this important information. He says, “Defendants use the results of the Rocket AF study, the Record studies, and the Einstein studies to promote Xarelto in their promotional materials, including the Xarelto website, which tout the positive results of those studies. However, defendants’ promotional materials fail to similarly highlight the increased risk of gastrointestinal bleeding and bleeding that required transfusion among other serious bleeding concerns.”
It has been alleged that manufacturers spent over $11 million to promote Xarelto through advertisements, some of which used celebrity endorsements. These ads brought them an estimated $582 million in sales during Xarelto’s first year on the market. The plaintiff maintains his argument that these manufacturers chose to purposefully mislead consumers by specifically emphasizing the benefits and overall effectiveness of the anticoagulant, while also neglecting to mention many of its potentially dangerous and even fatal side effects.
As these continually increasing Xarelto lawsuit plaintiffs await trial, Attorney Joseph Osborne is looking to help ensure that anyone who used Xarelto and also suffered from adverse health effects will have the opportunity to explore their legal rights fully. To help others wishing to pursue justice in the matter, Attorney Osborne is offering free consultations for qualifying individuals. Those affected may be entitled to legal action and substantial compensation.
To request additional information or ask questions, please contact Attorney Osborne by calling(866) 425-8902.
http://www.wrcbtv.com/story/31238549/xarelto-lawsuit-plaintiff-seeking-435-million-for-alleged-uncontrollable-bleeding-episode

Return to headline | Return to top
Bellwether Case Selection Completed For Xarelto Lawsuit MDL 2592 In Louisiana

Feb 17, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on the completed process of case selection for lawsuits consolidated in Xarelto multidistrict litigation number 2592, which are set to be heard in 2017. The MDL is being overseen by the Honorable Judge Eldon Fallon in the Eastern District of Louisiana. Today, the involved lawsuits number over 2,800 and all share common allegations against manufacturers Bayer AG and Janssen Pharmaceuticals’ (a division of Johnson & Johnson corporation) regarding their blood-thinning drug, Xarelto.
Plaintiffs in Xarelto multidistrict litigation 2592 claim that the drug puts patients at an increased risk of suffering from dangerous, sudden, uncontrollable bleeding episodes. Since the MDL’s initial formation in December of 2015, lawsuit numbers involved have steadily increased. Those close to the litigation anticipate that the numbers will continue to rise as time moves on.
The bellwether trial selection process was scheduled to begin shortly after the start of the new year, on January 11, 2016. Judge Fallon initially requested that defendants choose 10 representative cases and plaintiffs choose 10 representative cases to combine with 20 cases chosen by the court, forming a bellwether pool of 40 cases. From this pool, he required 4 bellwether cases to be selected with specific criteria, which are scheduled to be heard in 2017. Bellwether cases are conducted to help those involved get a better idea of how a jury might respond to evidence or testimony as cases move ahead to trial.
The U.S. Food and Drug Administration has now given Xarelto two black box warnings. These product warnings are the most strict that can be given by the FDA before the product is completely pulled from the market. Several studies have supported plaintiff’s allegations, linking the anticoagulant to episodes of bleeding, including stomach and eye bleeds.
Attorney Joseph Osborne is currently looking to assist anyone who has suffered from adverse health effects while using Xarelto. He hopes to help ensure that these patients will have the opportunity to fully explore their legal rights. They may be entitled to legal action and substantial compensation. To help encourage them to seek justice, Attorney Osborne is offering free legal consultations to affected parties at this time.
To request additional information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2840364#ixzz40cwlNUBU

Return to headline | Return to top
Xarelto Litigation – February Updates

Feb 17, 2016 | JD Supra Business Advisor

By Searcy Denney Scarola Barnhart & Shipley

There have been a number of recent noteworthy developments in the national litigation involving Xarelto. Currently, there are approximately 5,000 individual lawsuits pending in state and federal courts against the manufacturers of Xarelto. The largest concentration of state court cases is in Philadelphia, where nearly 600 individual lawsuits are pending. The state court litigation involves primarily those plaintiffs who are unable to participate in the MDL proceedings due to a lack of diversity jurisdiction, as the plaintiff resides in the same state where the drug manufacturer has a legal presence. The lawsuits that have been filed include a number of US and foreign drug companies, including Janssen Research & Development, LLC; Johnson & Johnson Pharmaceutical Research and Development, LLC; Johnson & Johnson Company; Janssen Ortho, LLC; Janssen Pharmaceuticals, Inc.; Janssen Pharmaceutica, Inc.; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Bayer Corporation; Bayer Healthcare AG; Bayer Pharma AG; Bayer Healthcare LLC: and Bayer Healthcare Pharmaceuticals Inc.
It is anticipated that hundreds of additional cases will be filed in the coming months, especially since Xarelto remains on the market and patients and their prescribing doctors are unaware of the mounting safety concerns over the drug. Xarelto was approved by the FDA on July 1, 2011, and quickly became a “blockbuster” drug with sales in excess of $2 billion in 2013. The drug also is noteworthy for its meteoric rise on the list of drugs with the most reported adverse events to the Food & Drug Administration.
Judge Fallon, the Louisiana federal court judge who oversees MDL No. 2592, held a hearing in New Orleans in the national coordinated proceedings on January 22, 2016. At this court hearing, the judge heard arguments from the lawyers for both sides on a number of issues relating to the production of corporate documents, depositions of employees involved in the development and marketing of Xarelto, and selection of individual cases for future trials in the MDL.
Some of these same issues have been the subject of numerous meetings and hearings late last year as well. In particular, the Defendants’ privilege logs and the documents that have been requested by the plaintiffs but not yet produced by the drug manufacturers due to claims of some legal protection such as attorney-client confidentiality or trade secrets have been the subject of many of these meetings and the parties await rulings from the judge.
There was a dispute between the parties over the plaintiffs’ efforts to obtain the personnel files with regard to employees who were involved in the development, marketing, and oversight of Xarelto. On January 26, 2016, the MDL judge issued an order denying the plaintiffs’ requests for wholesale production of personnel files, but ruled that the plaintiffs could raise the issue again on a case-by-case basis with a showing of how the relevancy of those records would outweigh any privacy concerns of the employee. The plaintiffs sought these files in hopes of showing motive and bias of the employees in, allegedly, rushing Xarelto to market as well as any misconduct with regard to the performance of their duties in connection with the design, production, and sale of Xarelto.
The first depositions in the national litigation began in late 2015. It is anticipated that dozens of depositions of the Defendants’ employees and third parties will continue over the next few months. Judge Fallon has been asked to rule on a number of issues relating to the upcoming depositions, including notice requirements, duration of questioning, use of multiple video cameras, use of translators, receipt of documents in advance of the depositions, and other issues that (if let unresolved) have, historically, impeded the discovery process.
Millions of pages of documents have also been produced with more documents expected to be produced in the coming weeks. The FDA’s records relating to Xarelto were subpoenaed in April of 2015, and that production began in the fall of 2015.
The ROCKET AF clinical trial (also known as the Rivaroxaban Once Daily Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation study) served as the basis for the FDA’s approval of Xarelto back in 2011. In this MDL, the plaintiffs have made allegations that irregularities in managing participants in the study and analyzing the data. Plaintiffs further argue that if the study had been properly conducted that it would have shown that Xarelto was actually less safe and had less efficacy than Coumadin (warfarin), and presumably, the FDA would have refused to approval the drug for sale in the United States (resulting in the avoidance of perhaps thousands of injuries and deaths to patients).
In the course of this litigation, the plaintiffs have learned that participants in the ROCKET AF study were issued a blood monitoring device known as an INRatio, manufactured by HemoSense), to measure how thin their blood was while taking warfarin. The monitoring device was recalled by the FDA in September of 2015, and there are now concerns that the patients in the study who were reported in the original study as being well-controlled on their warfarin doses may have actually had their true INR levels misreported. The effectiveness of warfarin in the study patients is highly relevant since it is the comparator drug for the patients who were taking Xarelto. If the patients were not in fact well-controlled on their warfarin doses, then the risks of bleeding events seen in the warfarin population in the study may be artificially high when compared to the same risks in study participants who were taking Xarelto.
According to the Defendants, researchers at Duke have reportedly reanalyzed the data from the original clinical trial following the INR device recall and have reached the same conclusions with regard to the safety and efficacy of Xarelto. Those results have not yet been published, and are part of the evidence sought by the plaintiffs from Duke and the Defendants in this litigation. Duke has also refused to produce the critical evidence thus far by arguing that production of the data re-analyses would infringe on pending proceedings before drug regulators in the European Union as well as Duke’s internal, peer-review process for scientific publications. A committee meeting of the European Medicines Agency (the equivalent of the FDA in the EU) regarding Xarelto and the reanalysis of ROCKET AF data is scheduled for January 25-28, 2016. Judge Fallon is expected to rule on these critical discovery issues in the coming weeks.
A motion has been filed by the Defendants requesting permission to have direct communications with the plaintiffs’ physicians. This ex partecontact is something that is opposed by the plaintiffs due to concerns about patient confidentiality and the potential for undue influence of the physicians. In most jurisdictions, Defendants are not permitted to speak directly with a plaintiff’s physician without either a court order, specific consent from the patient, or within the context of a deposition. It is expected that Judge Fallon will hear further argument on this very important issue at the hearing scheduled for February 23, 2016.
In the near future, Judge Fallon will release the list of the 40 cases that have been selected as a part of the first MDL bellwether trial pool. Of the 40 cases that will be selected for case-specific discovery and potential selection for the first trials in the MDL, 20 will be requested by the parties and 20 will be selected randomly by the judge. The cases selected must also involve fatal or non-fatal GI bleeds, rectal bleeds, or brain bleed (also known as a hemorrhagic stroke) and include plaintiffs from various age groups and indications for use of Xarelto (i.e., patients with atrial fibrillation who took the drug for stroke prevention versus patients who took Xarelto for prevention or treatment of a deep vein thrombosis or pulmonary emboli). Most of the plaintiffs will also be chosen from the states of Louisiana, Texas, and Mississippi. The trials are still expected to occur in February through March of 2017.
http://www.jdsupra.com/legalnews/xarelto-litigation-february-updates-80327/

Return to headline | Return to top
Xarelto Lawsuit Cases Alleging Dangerous Bleeding Risks Consolidated By JPML Under Honorable Judge Eldon Fallon

Feb 17, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on the consolidation of all federally-filed Xarelto bleeding lawsuits by the U.S. Judicial Panel on Multidistrict Litigation. The 2,800 cases are being overseen by the Honorable Judge Eldon E. Fallon in the Eastern District of Louisiana, who will hold another monthly status meeting regarding their progress toward the end of February of 2016. This consolidation initially took place on December 12, 2015, initiating a transfer of cases filed in federal courtrooms across the nation. Since the consolidation, lawsuit numbers in the MDL have continued to experience a significant growth in number.
Consolidation of these many cases was possible due to the fact that the plaintiffs involved shared strikingly common allegations against the same defendants: Bayer AG and Janssen Pharmaceuticals (a division of parent company Johnson & Johnson). Consolidation is done to help fast track the litigation by avoiding duplicate discovery items and different rulings from multiple judges. It also helps to conserve resources, such as time and finances of everyone involved.
The MDL consolidation was first requested by a group of plaintiffs, who submitted the request in October of 2015. They asked that all involved lawsuits be centralized in the Southern District of Illinois, however, defendants fought this request, arguing that the lawsuits should be housed in New Jersey because of the companies’ locations.
Following a hearing session on December 4, 2015, the JPML stated, “In our judgement, the considerable growth in the litigation over the past few months demonstrates that informal coordination is not practical.” They also indicated that they had determined that the involved cases would be presided over by the Honorable Judge Eldon Fallon, noting, “Judge Eldon E. Fallon, who presides over three potential tag-along (Xarelto) actions, is an experienced transferee judge with the willingness and ability to manage this litigation efficiently. He is well-versed in multidistrict litigation, and we are confident he will steer this matter on a prudent course.”
While all involved plaintiffs await trial, Attorney Joseph Osborne is working to ensure that others who have suffered while taking Xarelto will also be given the opportunity to fully explore their legal rights. To help encourage this process, he is offering free legal consultations to affected parties at this time. These patients and their families may be entitled to legal action and substantial compensation.
To request more information or ask questions at any time, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.keyc.com/story/31249365/xarelto-lawsuit-cases-alleging-dangerous-bleeding-risks-consolidated-by-jpml-under-honorable-judge-eldon-fallon

Return to headline | Return to top
Xarelto Lawsuit Plaintiffs Look For Results Of Investigation Of European Regulators Into Drug’s Clinical Trials

Feb 17, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on an investigation by European regulators regarding the results of Xarelto clinical trials. This investigation closely follows an ongoing increase in lawsuits filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation) which commonly allege that use of their blood thinner Xarelto can put patients at an increased risk of spontaneous and dangerous uncontrollable bleeding events.
The clinical trial currently under investigation was completed at the Duke Institute for Clinical Research. Details provided in the Project On Government Oversight (POGO) appear to show that the official issuing the U.S. Food and Drug Administration’s 2011 approval of anticoagulant Xarelto had expressed some sincere concerns regarding the safety of the drug, and the approval itself was met with some serious contention from within the organization.
According to details released by POGO, “The FDA approved Xarelto in 2011 over the objections of the primary FDA scientists assigned to study its safety and effectiveness. The report by the reviewers argued that patients could be ‘at greater risk of harm from stroke and/or bleeding’ if they took Xarelto than if they were treated skillfully with Warfarin, a blood thinner that has been on the market since the 1950’s.”
Giving further detail about this potential product objection, POGO states, “The official who issued the FDA’s decision to approve the drug expressed a series of misgivings about it.” They now note that this official, named as FDA Deputy Division Director Stephen M. Grant made comments about the decision to approve the product which indicated some of his concerns. He stated, “The decision was made difficult by the limitations in the design and conduct” (of the clinical trial). This statement was recorded in a November 2011 memo.
Today, blood-thinning drug Xarelto is the topic of over 2,800 lawsuits filed in federal courtrooms across the nation and then consolidated and transferred to the Eastern District of Louisiana. The cases are continually growing in number and are presided over by the Honorable Judge Eldon Fallon. The U.S. Judicial Panel’s consolidation of these cases formed MDL No. 2592.
Since its initial approval by the FDA, Xarelto has been issued two black box warnings by the organization. These are the most serious warnings possible before completely pulling the product from the market. The European investigation on clinical trials surrounding Xarelto was discussed in further detail on AllGov.org, which stated, “The clinical trial relied on blood testing devices that were the subject of two FDA warning letters before the trial began and an FDA recall notice after the trial ended, according to the Project on Government Oversight (POGO). Certain devices in the INRatio product line, the warning notice read, could deliver false test results and that use of those devices may ‘cause severe or life-threatening injuries, including death’”.
The latest released details of this investigation indicate that the EMA, “is currently investigating whether the data generated from the INRatio device could have had any impact on the trial results and the extent of this impact, if applicable.” Last month as well, POGO reported that a preliminary FDA staff review of the clinical trials indicated that they may be biased in favor of Xarelto approval. As these investigations continue to delve deeper, the ever-increasing number of plaintiffs involved in Xarelto litigation anxiously await their results.
At this time as well, Attorney Joseph Osborne is working to help ensure that patients who believe they were negatively affected by Xarelto will have the opportunity to fully evaluate their legal rights. It is believed that these individuals may be entitled to significant compensation. To help those interested in pursuing justice, Attorney Osborne is currently offering free legal consultations to affected parties.
To request additional Xarelto information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2840241#ixzz40cyU1ILw

Return to headline | Return to top
Xarelto Lawsuit Alleges Manufacturers Bayer And Janssen Are Responsible For Patient’s Life-Threatening Injuries

Feb 18, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports details from a lawsuit filed against Xarelto manufacturers Bayer Healthcare and Janssen Pharmaceuticals (a subsidiary of corporate giant Johnson & Johnson). The complaint was filed by a married couple from Ohio who allege that their blood thinner caused the wife to suffer from a sudden, life-threatening internal bleeding episode. Together, the pair are requesting compensation of over $150,000 to help manage current and future medical bills, as the bleed has allegedly left her with long-term damage and a need for continued medical care.
Details from the lawsuit filing, which now joins more than 2,800 other lawsuits as a part of multidistrict litigation number 2592, indicate that the plaintiff was prescribed Xarelto (rivaroxaban) by a family physician in order to treat her atrial fibrillation; a common heart condition which can put sufferers at increased risk for strokes. As a preventative measure, many who suffer from this condition are placed on blood thinners.
After just two months of taking Xarelto, the woman suddenly suffered from a severe gastrointestinal bleed and anemia, as well as several other unspecified injuries. The plaintiffs report that she continues to require regular medical care for sustained injuries from this bleeding episode.
In 2011, the U.S. Food and Drug Administration (FDA) gave Xarelto approval, and the anticoagulant launched onto the market as a revolutionary new-generation blood thinner. It was initially approved to reduce the risk of blood clots or strokes in patients recovering from hip and knee replacement surgeries, and those with deep vein thrombosis. Later, the FDA expanded their approval to include Xarelto treatment for patients with atrial fibrillation, as was the case or this plaintiff. Since then, however, the FDA has placed two black box warnings on the drug, which is the most severe warning a product can receive before being removed from the market.
Now, Xarelto is the current topic of more than 3,000 lawsuits which have been filed all across the nation. Plaintiffs filing these complaints all similarly claim that the anticoagulant puts users at increased risk of dangerous, uncontrollable bleeding episodes, some of which have proven fatal. Over 2,800 of these cases were consolidated by the JPML to form MDL No. 2592. The MDL is being overseen in New Orleans, Louisiana by the Honorable Judge Eldon Fallon. There is also another group of over 550 strikingly similar Xarelto lawsuits which have formed a mass tort group in Philadelphia, Pennsylvania.
Many involved anticipate that Xarelto cases will continue to increase in number across the board. Attorney Joseph Osborne is working to help assist those who believe they were negatively affected by Xarelto. He believes these patients and their families may be entitled to significant compensation, and greatly encourages them to explore their legal opportunities in full. To help encourage deserving people to pursue justice, Attorney Osborne is offering free legal consultations to affected persons at this time.
To request additional information, or to ask questions about Xarelto bleeding lawsuits, please contact Joseph Osborne, Esq., by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2842071#ixzz40cyBsbVt

Return to headline | Return to top
Xarelto Lawsuit Plaintiff Claims Anticoagulant Drug Caused Life-Threatening Internal Bleed

Feb 18, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on a lawsuit which has been filed against Xarelto manufacturers Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer Healthcare initially filed in the Eastern District of New York. The suit was filed by a woman from Texas who claims that the manufacturers failed to warn patients (including herself) about the potential risks associated with their blood-thinning drug. The lawsuit was filed under case number 1:14-cv-04524.
The plaintiff involved states that she was prescribed Xarelto by her physician to prevent the risk of stroke due to her atrial fibrillation condition. She indicates that she was only taking the blood thinner for 5 months when she suddenly suffered from an internal bleed which doctors deemed life threatening. Although she survived this bleed, she says that she has now been left with long-term medical needs because of it.
In 2011, Xarelto gained approval from the U.S. Food and Drug Administration (FDA). It was a new-generation blood thinner which required none of the regular physician monitoring, dosage adjustments or dietary restrictions that traditional blood thinners had. The FDA approved the drug to treat patients who had recently undergone hip and knee replacement surgeries, or who had deep vein thrombosis. This use was later expanded to include treatment for patients with atrial fibrillation.
Today, Xarelto lawsuit plaintiffs continue to file suit against the drug’s manufacturers. All share similar allegations that the drug puts users at increased risk for sudden dangerous bleeding events. Lawsuits filed in federal courts from across the nation have now been consolidated to form multidistrict litigation number 2592. This consolidation was done by the U.S. Judicial Panel on Multidistrict Litigation, and now involves over 2,800 lawsuits in the Eastern District of Louisiana. These cases are being overseen by the Honorable Judge Eldon Fallon, and the consolidation should help the litigation surrounding them to run more efficiently and quickly.
As the plaintiffs anxiously await their day in trial, Attorney Joseph Osborne is working to help ensure that everyone who feels that they have been negatively affected by the blood thinner will have the option of evaluating their legal rights in full. Patients who used Xarelto and who also suffered from adverse health events which they attribute to the drug may be entitled to legal action and substantial compensation. To help these individuals seek justice, Attorney Osborne is currently offering complimentary Xarelto consultations.
To request additional information, or to ask questions regarding Xarelto bleeding lawsuits, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2840991#ixzz40cyrOP1M

Return to headline | Return to top

Plaintiff Attorney Blog Posts

Xarelto

Feb 13, 2016 | Injury Lawsuit Help

WHAT IS XARELTO® ?
If you take the prescription medication XARELTO which is used to reduce the risk of stroke and blood clots in people with atrial fibrillation, not caused by a heart valve problem. This prescription medicine used to treat deep vein thrombosis and pulmonary embolism, and to help reduce the risk of these conditions occurring again. If you experience any type of severe issues, call your doctor immediately. Then call us.
Recently, consumers have begun bringing suits against the manufacturers of Xarelto for failure to warn consumers of adverse side effects. These Xarelto side effects include uncontrolled internal bleeding, pulmonary embolism, deep vein thrombosis, ischemic strokes, embolism and strokes, and in most severe cases death. Xarelto Lawsuit Information
The manufacturers being sued in the Xarelto class action lawsuits are Bayer and Johnson & Johnson’s Janssen Pharmaceuticals. The suits cite the manufacturers’ neglect to warn consumers of all side effects and not properly informing doctors of a solution to reverse uncontrolled and internal bleeding. Currently our lawyers are accepting Xarelto cases from individuals who have experienced adverse side effects. Most recently Xarelto lawsuits have been consolidated into multi-district litigation in order to better streamline the process.
Blood thinners can cause bleeding and result in death. You may have a higher risk of bleeding if you take blooding thinners with other medications like and including: Aspirin or aspirin-containing products, Non-steroidal anti-inflammatory drugs (NSAIDs), Warfarin or Coumadin, Any medicine that contains Heparin, Clopidogrel
http://www.injurylawsuithelp.com/xarelto/

Return to headline | Return to top
Drug Injury Lawsuits

Feb 15, 2016 | Drug Justice

What Is Xarelto? Xarelto® (rivaroxaban), a Bayer and Johnson & Johnson Janssen Pharmaceutical product, is an oral anticoagulant blood thinner that has been on the market since 2011. Xarelto is extremely popular amongst consumers in the United States due to its ability to treat a variety of medical issues including: reducing the risk of blood clots and strokes in people with atrial fibrillation, treating deep vein thrombosis and pulmonary embolism and also reducing the risk of blood clots in patients who have recently had hip or knee replacement surgery.
Xarelto has recently received backlash for its failure to warn consumers of its adverse side effects, leading to a class action lawsuit. Xarelto side effects include uncontrolled internal bleeding, pulmonary embolism, deep vein thrombosis and in most severe cases death.
Xarelto Lawsuit Information Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are being sued in the lawsuit primarily due to their neglect to warn consumers of all Xarelto side effects and not properly informing doctors of a solution to reverse uncontrolled and internal bleeding. The lawyers on the case are currently looking for patients that have experienced internal bleeding and blood clots and the families of victims who have died after taking this drug. The Xarelto lawsuit has most recently been consolidated into a multi-district litigation in order to better streamline the process.
This isn’t the first time a blood thinner has been amidst public scrutiny. Pradaxa (dabigatran), a drug similar to Xarelto has had thousands of lawsuits filed against it due to its failure to warn consumers of its associated risks. Similar side effects that may occur with the Xarelto blood thinner have been seen in Pradaxa as well as Eliquis, which is currently under suit for the same reasons. It’s believed that the Eliquis and Xarelto lawsuits will have the same magnitude of claims filed due to their popularity amongst consumers in the United States.
https://www.drugjustice.com/xarelto-lawsuit/

Return to headline | Return to top
Judge Outlines Categories for Xarelto Bellwether Trials

Feb 16, 2016 | Top Class Actions

By Ashley Vanover

A case management order has been issued in the Xarelto multi district litigation (MDL) that outlines the injury categories into which Xarelto lawsuits must be classified to be considered for potential bellwether trials.
These bellwether cases are scheduled as part of the larger multidistrict litigation created to manage thousands of cases related to the allegations that the blood thinner medication causes serious internal bleeding problems.
U.S. District Judge Eldon Fallon issued Case Management Order No. 4 on Dec. 17 to outline the next steps in the discovery process for the MDL, which is taking place in the Eastern District of Louisiana.
The bellwether trials will help to determine a jury’s response to the evidence presented regarding alleged
Xarelto problems, set precedent for future trials, and encourage large-scale settlements.
Participants are engaged in a general discovery process to apply to all cases at this time. However, by issuing the order related to possible injury categories, Judge Fallon grouped potential lawsuits to be representative of distinct types of alleged Xarelto injuries.
Xarelto Injury Categories
Judge Fallon broke down categories for Xarelto lawsuits in connection to the type of Xarelto injury and reason for prescription. Xarelto injury types include:
Gastrointestinal bleeding
Rectal bleeding
Brain bleed/hemorrhagic stroke
Each Xarelto lawsuit proposed as a bellwether case is to be classified according to the severity of the injury, for example gastrointestinal bleeding is more serious than a nosebleed, if both were alleged as injuries in a single case.
The reasons for prescribing Xarelto were also set forth into three categories: reducing the risk of stroke, treating deep vein thrombosis, or treating a pulmonary embolism.
Both the defense and plaintiff attorneys submitted 10 possible cases to be included in the Xarelto bellwether pool in mid-January, with specific quotas for cases based on the state of origin.
Both sides were encouraged to pick cases that fall into each of the categories outlined above, though there is no specific requirement that they do so. The court itself also added 20 cases to the pool on Jan. 15. Bellwether trials are expected to take place between February and May of 2017.
Xarelto Lawsuits
Over 2,400 federal Xarelto lawsuits have been filed over internal bleeding complications alleged by plaintiffs. The drug hit the market in 2011 and was touted as a superior treatment compared to the standard blood-thinner, warfarin.
It was reportedly less complicated to use, requiring less frequent blood monitoring and less dietary restrictions. However, subsequent studies have questioned many of the initial claims put forward about Xarelto, including the claim that the drug is safer than the industry standard warfarin.
At the core of many Xarelto problems is the fact that Xarelto lacks an antidote should internal bleeding occur, leading doctors with few options to treat a life-threatening bleed in the brain and gastrointestinal tract. By comparison, a bleeding even associated with Warfarin can be reversed with a dose of Vitamin K and fresh frozen plasma.
If you or a loved one suffered from serious Xarelto problems or complications including gastrointestinal bleeding or hemorrhaging, you may be able to file a Xarelto lawsuit.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Xarelto attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Xarelto class action lawsuit is best for you. [In general, Xarelto lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/327063-case-management-order-outlines-categories-for-xarelto-injury-trials/

Return to headline | Return to top
Parties Select Xarelto Bellwether Cases, Litigation Moves Forward

Feb 17, 2016 | The Legal Examiner

By Andy Childers

The U.S. District Court in the Eastern District of Louisiana has started the process of selecting 40 cases for the bellwether trial pool.
As required by an order dated December 17, 2015, the parties in the Xarelto multidistrict litigation (MDL) have selected 10 cases for the pool by the January 11, 2016 deadline: Five originating in the Eastern District of Louisiana; One from Mississippi; One from Texas; Three from other states.
An additional 20 lawsuits were scheduled to be selected by January 15, 10 from Louisiana, two from Mississippi, and one case from eight other states. The first two Xarelto bellwether trials are scheduled to begin in February 2017 in the Eastern District of Louisiana on February 6 and March 13. The third and fourth trials are set for Mississippi and Texas on April 24 and May 30, respectively.
Approximately 2,400 cases against Xarelto makers Bay and Janssen Pharmaceutical Division are pending in MDL 2592, centralized in the Eastern District of Louisiana.
What is Xarelto?
Xarelto is a new generation anticoagulant developed by Bayer Healthcare and Johnson & Johnson’s Janssen Pharmaceuticals subsidiary in 2011 as a superior alternative to warfarin (Coumadin), the blood thinner used widely since the 1950s for the prevention of strokes in those suffering from atrial fibrillation (irregular heart beat). These patients are at increased risk of formed a blood clot in the heart, which can travel to the brain and cause a stroke.
Xarelto works by thinning the blood, lowering the chance of clots forming. Although all blood thinners increase the risk of bleeding problems, Xarelto has been linked to an increased number of uncontrollable blood injuries because there is no approved antidote available for patients who use Xarelto, and many of the side effects have been severe because the bleeding cannot be effectively controlled.
http://atlanta.legalexaminer.com/defective-dangerous-products/parties-select-xarelto-bellwether-cases-litigation-moves-forward/

Return to headline | Return to top
Xarelto- Blood Thinner Lawyer News

Feb 17, 2016 | Jewish Lawyers USA

XARELTO LAWYERS FILING BLOOD THINNER EXTENSIVE BLEEDING LAWSUITS
Xarelto Is A Blood Thinner With Dangerous Side Effects Xarelto is a blood thinner with no antidote. Xarelto has been shown to cause extensive bleeding resulting in severe injury and deaths. The Xarelto lawyers are moving ahead with the Xarelto bleeding lawsuits in a multi district litigation. This MDL consolidates the Xarelto lawsuits in one location under one judge.
XARELTO LAWSUITS MOVE AHEAD
The Multi-district litigation is moving forward for extensive bleeding cases related to Xarelto Discovery is continuing in the multi-district litigation (MDL) of cases related to bleeding from Xarelto. Xarelto a prescription blood thinner used to reduce the risk of blood clots. Plaintiffs who are bringing Xarelto lawsuits claim that the warnings for the blood thinner are inadequate. Plaintiffs have alleged that Xarelto has an increased risk of uncontrolled bleeding, strokes, blood clots and brain hemorrhages resulting in serious injury and death.
XARELTO EXTENSIVE BLEEDING LAWYERS
Did Xarelto cause an extensive bleeding injury or death of a loved one? Did the bleeding event occur after January 2012? Do you have your medial records that say you or they took Xarelto? Did you take Xarelto and develop uncontrolled bleeding or another serious complication?Did you lose a loved one due to extensive bleeding from Xarelto?
XARELTO HAS WARNINGS FOR SEVERE COMPLICATIONS INCLUDING:
Internal Bleeding, Blood Clots, Gastrointestinal bleeding- bleeding ulcers Embolism, Hemorrhaging, Brain Bleed Xarelto lawyers are currently accepting Xarelto excessive bleeding cases nationwide
http://www.jewishlawyersusa.com/xarelto-blood-thinner-lawyer-news/

Return to headline | Return to top
Xarelto Lawsuit Alleges Drug Caused Woman Two Gastrointestinal Bleeds

Feb 17, 2016 | Top Class Actions

By Joanna Szabo

A New Jersey resident recently filed a Xarelto blood thinner lawsuit against Janssen Pharmaceuticals, alleging that use of the anticoagulant drug led to serious gastrointestinal bleeding.
Plaintiff Sharon M. first began taking Xarelto in November 2013 and stopped taking the drug in April 2014 after experiencing two serious gastrointestinal bleeding events in less than two months.
According to the Xarelto blood thinner lawsuit, Sharon claims that her ingestion of Xarelto caused not only serious gastrointestinal bleeding but also led to physical pain and mental anguish. These Xarelto side effects also necessitated hospitalization and medical treatment, causing Sharon to suffer financially as well.
The blood thinner lawsuit further alleges that Xarelto was not adequately tested by Janssen, but that it sold the anticoagulant without proper testing or warning for the potentially severe side effects.
Sharon claims that had she been properly informed of Xarelto’s potential dangers and side effects, she would not have taken the blood thinner medications and could have avoided serious gastrointestinal bleeding and other side effects altogether.
Xarelto Basics
Xarelto (rivaroxaban) is a popular anticoagulant medication developed and sold by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
Janssen reports that Xarelto has been prescribed to over seven million people across the world, helping prevent dangerous blood clots. Yet despite Janssen’s claims that Xarelto is capable of preventing dangerous clotting complications, this blood thinner lawsuit — and others like it — allege that the company’s fervent marketing misinformed patients and the medical community.
According to these Xarelto lawsuits, Janssen deliberately underplayed the drug’s safety and efficacy. Rather than being superior to warfarin (an anticoagulant staple drug), Xarelto is allegedly no safer to use, and like warfarin, should require routine blood monitoring.
Xarelto Side Effects
This Xarelto blood thinner lawsuit and others like it allege that recent studies and reports have revealed a link between Xarelto and major bleeding events, such as serious gastrointestinal bleeding.
Xarelto bleeding lawsuits claim that Janssen was not only aware of these studies and the bleeding risks of Xarelto, but it failed to report these major bleeding complications as significant adverse effects and continued to market Xarelto in a manner lawsuits describe as negligent and misleading.
Xarelto Blood Thinner Lawsuits
Janssen is currently facing hundreds of Xarelto blood thinner lawsuits filed for patients who, after taking the anticoagulant, have experienced serious gastrointestinal bleeding, hemorrhaging, or other adverse bleeding events.
If you or someone you know has experienced Xarelto side effects such as serious gastrointestinal bleeding, you may be able file a Xarelto bleeding lawsuit.
The Xarelto Blood Thinner Lawsuit is Case No. 2:15-cv-07120 in the U.S. District Court for the Eastern District of Louisiana.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Xarelto attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Xarelto class action lawsuit is best for you. [In general, Xarelto lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/327160-nj-woman-files-xarelto-lawsuit-two-gastrointestinal-bleeds/

Return to headline | Return to top
Xarelto Lawsuit: Blood Thinner Caused Intracranial Hemorrhage

Feb 19, 2016 | Top Class Actions

By Tamara Burns

A new Xarelto lawsuit was filed as part of the multidistrict litigation underway in a Louisiana federal court alleging that the blood thinner caused one man to suffer a life-threatening intracranial hemorrhage.
Plaintiff Otis F. used Xarelto to reduce his risk of stroke and systemic embolism from atrial fibrillation, an abnormal heart rhythm.
According to the Xarelto lawsuit, he was prescribed the blood thinner medication in August 2013 and suffered a serious and irreversible intracranial hemorrhage in January 2014 allegedly as a direct result of his use of Xarelto.
Additionally, Otis claims he experienced other permanent and lasting personal injuries including severe physical pain and mental anguish, including loss of enjoyment of life expenses for medical treatment and hospitalization, and a loss of earnings due to the complications he attributes to his use of Xarelto.
Otis brings forth nine counts against Janssen in the Xarelto lawsuit including negligence, strict products liability, fraudulent misrepresentation and violation of consumer protection laws,
He is seeking punitive, compensatory and other damages in the form of medical expenses, lost earnings and other economic damages, and costs associated with filing the Xarelto lawsuit.
Xarelto Safety Concerns
Xarelto (rivaroxaban) is an oral anticoagulant medication used to treat atrial fibrillation and prevent embolisms (blood clots) including deep venous thrombosis (DVT) and pulmonary embolism (PE).
Xarelto was approved by the FDA in 2011 as an alternative to an older blood thinning agent, warfarin (Coumadin), that had been the primary oral anticoagulant in use since the 1950s. Xarelto’s ease of use and success in treating conditions made it a popularly prescribed drug very quickly.
Unfortunately, Xarelto also came with unintended side effects that were not so much of an issue with warfarin. Patients using Xarelto were at an increased risk for suffering from uncontrollable bleeding events.
While this was also a concern with warfarin, but there was a reversal agent that worked to stop any internal bleeding events. Fresh frozen plasma and vitamin K were used to successfully stop bleeding in warfarin patients and did so fairly quickly and efficiently.
For Xarelto, there is currently no antidote for bleeding events, and for some individuals, this can be life threatening and even fatal. The most that can be done for Xarelto bleeding currently is to have patients stop the medication and have hospital personnel try to stabilize the patient while the effects of the blood thinner wear off.
Xarelto patients may experience internal bleeding in a variety of locations such as an intracranial hemorrhage in the brain like Otis experienced, gastrointestinal bleeding, or at other locations. Some patients experience transient damage, while others suffer permanent damage or do not survive the excessive blood loss.Filing a Xarelto Lawsuit
If you or a loved one has suffered severe bleeding side effects as a result of using Xarelto, you may be eligible to file a Xarelto lawsuit. A Xarelto attorney can review your case at no charge and can discuss the legal options that are available to you.
The Xarelto Lawsuit is Case No. 2:16-cv-00241 and is part of the Xarelto MDL No. 2529 In Re: Xarelto (Rivaroxaban) Products Liability Litigation, Case No. 2:14-md-02592, in the U. S. District Court for the Eastern District of Louisiana.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Xarelto attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Xarelto class action lawsuit is best for you. [In general, Xarelto lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/327118-327118/

Return to headline | Return to top

Full Text of Stories Below

Add recipients

Suggested